Clinical trials: Angina
Angina
Effect of Febuxostat Compared to Placebo on Exercise Tolerance in Participants With Chronic Stable Angina
The purpose of this study is to evaluate the effect of febuxostat, once daily (QD), compared to placebo as an add on to stable anti-anginal therapy, on the total exercise time of participants with Chronic Stable Angina.
- Trial name
- NCT01549977
- Testing
- Febuxostat
- Where
- 21 sites in United States
- Volunteers
- 1 people
- Sponsor
- Takeda
Refractory Angina, Coronary Artery Disease
Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina.
This is a two-part study, comprised of an initial open-label run-in phase (Part 1) in a subset of 3 subjects to provide first data regarding safety, and feasibility of the percutaneous endovascular catheter-facilitated…
- Trial name
- EXACT2 (NCT07048808)
- Testing
- XC001
- Where
- 14 sites in United States
- Volunteers
- 106 people
- Sponsor
- XyloCor Therapeutics, Inc.
Angina, Hypertension
To Demonstrate the Relative Bioavailability of Atenolol Tablets, 100 mg
To demonstrate the relative bioavailability of atenolol tablets, 100 mg.
- Trial name
- NCT00946725
- Testing
- Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical), Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Sandoz
Angina Pectoris, Coronary Heart Disease
A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014)
This study will assess the safety of telcagepant in coronary artery disease (CAD) participants with stable angina during exercise treadmill testing and evaluate whether calcitonin gene-related peptide (CGRP) receptor antagonism…
- Conditions
- Angina Pectoris, Coronary Heart Disease, Calcitonin Gene-related Peptide Receptor
- Trial name
- NCT01294709
- Testing
- telcagepant
- Volunteers
- 64 people
- Sponsor
- Merck Sharp & Dohme LLC
Coronary Artery Disease, Ischemia
Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial)
The primary purpose of this trial is to determine the safety of XC001 (AdVEGFXC1) in patients who suffer from angina caused by coronary artery disease and have no other treatment options.
- Conditions
- Coronary Artery Disease, Ischemia, Angina Refractory, Cardiovascular Diseases
- Trial name
- EXACT (NCT04125732)
- Testing
- AdVEGFXC1
- Where
- 16 sites in United States
- Volunteers
- 41 people
- Sponsor
- XyloCor Therapeutics, Inc.
Stable Angina, Unstable Angina
Clinical Performance of CRE8 Drug Eluting Stent in All Comer Population
The aim of this study is to evaluate safety and efficacy performances of CRE8 Drug Eluting Stent, in patients comparable to the everyday's clinical practice population, with a specific focus on diabetics, that will be part of a…
- Conditions
- Stable Angina, Unstable Angina, Acute Myocardial Infarction
- Trial name
- PARTICIPATE (NCT01556126)
- Testing
- Amphilimus Eluting Stent (CRE8)
- Where
- 23 sites in Austria, Belgium and 4 more
- Volunteers
- 1,191 people
- Sponsor
- CID - Carbostent & Implantable Devices
Stable Angina, Unstable Angina
Prospective, Single-arm, Multicenter Study for Evaluation the Safety and Effectiveness of the ALEX Stent in a Real-world Setting of Percutaneous Coronary Interventions in Patients With Coronary Heart Disease
To evaluate the safety and effectiveness of the ALEX stent in a real-world setting of percutaneous coronary interventions in patients with coronary heart disease.
- Conditions
- Stable Angina, Unstable Angina, Myocardial Infarction
- Trial name
- ALEX OCT (NCT01637012)
- Testing
- Implantation
- Where
- 5 sites in Poland
- Volunteers
- 60 people
- Sponsor
- Balton Sp.zo.o.
Essential Hypertension With Stable Angina and Dyslipidemia
A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.
The purpose of this study is to evaluate the effects of oral azilsartan once daily for 32 weeks on coronary artery plaque in essential hypertensive patients with stable angina and dyslipidemia.
- Trial name
- ALIVE (NCT02400775)
- Testing
- Azilsartan
- Where
- Japan
- Sponsor
- Takeda
Stable Angina, Acute Coronary Syndrome
Novasight Hybrid Intravascular Ultrasound and Optical Coherence Tomography System (IVUS OCT)
Collection of coronary images with a hybrid IVUS OCT system.
- Trial name
- NCT03484975
- Testing
- Observation group
- Where
- Canada
- Volunteers
- 23 people
- Sponsor
- Conavi
Stable Angina, Unstable Angina
International Randomized Comparison Between DES Limus Carbostent and Taxus DES in the Treatment of De-novo Coronary Lesions
The purpose of this study is to demonstrate non-inferiority in terms of safety and efficacy of DES Limus Carbostent compared to the Taxus Liberté in treating de-novo atherosclerotic lesions in native coronary arteries.
- Conditions
- Stable Angina, Unstable Angina, Documented Silent Ischemia
- Trial name
- NEXT (NCT01373502)
- Testing
- DES Limus Carbostent, Taxus Liberté Stent
- Where
- 11 sites in Belgium, France and 2 more
- Volunteers
- 323 people
- Sponsor
- CID - Carbostent & Implantable Devices
Chronic Total Occlusion of Coronary Artery, Chronic Angina
VasoStar Vibrational Guidewire System to Facilitate Crossing Coronary Artery Chronic Total Occlusions
The goal of this project is to provide an improvement in wire performance to expedite crossing difficult lesions in the coronary vasculature.
- Trial name
- VST100 (NCT06193954)
- Testing
- VasoStar guidewire system
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- VasoStar, LLC
Acute Coronary Syndromes
A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta
To identify the following items through the post marketing surveillance under routine clinical practice after marketing authorization of Brilinta Tablet: the occurrence of unrevealed Serious Adverse Events (SAEs), current status…
- Trial name
- NCT01611272
- Where
- 23 sites in South Korea
- Volunteers
- 3,402 people
- Sponsor
- AstraZeneca
Stable Angina, Myocardial Infarction
Safety Evaluation of Clopidogrel Sulfate in Patients With Stable Angina/Old Myocardial Infarction to Whom Percutaneous Coronary Intervention is Being Planned
Primary objective: To evaluate whether 12 weeks of clopidogrel is superior to ticlopidine in terms of lower risk of the safety events of interest in patients with stable angina (SA) or old myocardial infarction (OMI) to which…
- Trial name
- CLEAN (NCT00821834)
- Testing
- clopidogrel (SR25990), ticlopidine
- Where
- Japan
- Volunteers
- 1,003 people
- Sponsor
- Sanofi
Angina Pectoris
Efficacy and Safety of Lacidipine in Chronic Stable Angina
The aim of this study was to explore whether lacidipine at doses of 2 mg, 4 mg and 6 mg decreased the symptoms of angina, compared to placebo in patients with chronic stable angina
- Trial name
- NCT02232607
- Testing
- Lacidipine, low dose, Lacidipine, medium dose, Lacidipine, high dose
- Volunteers
- 283 people
- Sponsor
- Boehringer Ingelheim
Hypertension, Angina Pectoris
Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
In this survey, to collect the safety and efficacy information of Amlodipine /Atorvastatin (Caduet® Combination Tablets) in daily medical practice will be examined.
- Conditions
- Hypertension, Angina Pectoris, Hypercholesterolemia, Familial Hypercholesterolemia
- Trial name
- NCT01107743
- Testing
- Amlodipine/Atorvastatin
- Volunteers
- 1,291 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Angina
Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention (REPTAR)
The post-marketing study is designed to evaluate the activity level and exercise tolerance of patients with deferred percutaneous intervention due to FFR (fractional flow reserve) greater or equal to 0.81 and treatment with…
- Trial name
- REPTAR (NCT03044964)
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Amit Malhotra, MD
Stable Angina
Stable Angina Observational Registry
The purpose of this study is to describe the clinical profile and current status of the diagnosis and management of stable angina in India by non-interventional consulting physicians (CP) through a large multicenter observational…
- Trial name
- STAR (NCT01552109)
- Where
- India
- Volunteers
- 2,079 people
- Sponsor
- Medtronic Vascular
Acute Coronary Syndromes
Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction
While troponin is not detectable until several hours after an Acute Myocardial Infarction (AMI), copeptin is expected to be elevated very early after an AMI.
- Trial name
- CHOPIN (NCT00952744)
- Where
- 11 sites in United States
- Volunteers
- 2,071 people
- Sponsor
- Brahms AG
Acute Coronary Syndrome, Myocardial Infarction
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients with a recent acute coronary…
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia, Unstable Angina
- Trial name
- NCT00809965
- Testing
- Rivaroxaban 2.5 mg, Rivaroxaban 5 mg, Standard of care
- Where
- 556 sites in United States, Argentina and 41 more
- Volunteers
- 15,526 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Stable Coronary Artery Disease
A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders
The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet medication, affects platelets. Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of…
- Trial name
- RESPOND (NCT00642811)
- Testing
- Ticagrelor, Clopidogrel, Aspirin
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 98 people
- Sponsor
- AstraZeneca